The integration of SHAP analysis not only enhanced the interpretability of the model but also identified critical biomarkers such as tumor capsule absence, elevated HBV-DNA, CA125 levels and tumor diameter, and lower body weight as key predictors of recurrence risk. This evidence concerns the gene MUC16 and neoplasm.